Scientists focus on new immunotherapeutic approaches studied in advanced melanoma previously treated by anti-programmed cell death 1 (PD-1) receptor or anti-cytolytic T-lymphocyte-associated protein 4 (CTLA-4) antibodies.
[Current Opinion in Oncology]
Sorry, but the selected Zotpress account can't be found.